sulfasalazine has been researched along with Familial Spastic Paraparesis, Htlv-1-Associated in 1 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakagawa, M | 1 |
| Nakahara, K | 1 |
| Maruyama, Y | 1 |
| Kawabata, M | 1 |
| Higuchi, I | 1 |
| Kubota, H | 1 |
| Izumo, S | 1 |
| Arimura, K | 1 |
| Osame, M | 1 |
1 trial available for sulfasalazine and Familial Spastic Paraparesis, Htlv-1-Associated
| Article | Year |
|---|---|
Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory A | 1996 |